SAN DIEGO, May 13 /PRNewswire-FirstCall/ -- Santarus, Inc. today announced that a live audio webcast and accompanying slide presentation will be provided for its analyst day and investor briefing event "Santarus: What's New?".
Details of the event are as follows:
AGENDA
Welcome
Martha Hough, Vice President, Finance & Investor Relations, Santarus, Inc.
Santarus - What's New?
Gerald Proehl, President, Chief Executive Officer & Director, Santarus, Inc.
Commercial Update - ZEGERID(R)/GLUMETZA(R) and Overview of Lower GI Markets
William Denby, Senior Vice President, Commercial Operations, Santarus, Inc.
MMX(R) Technology - The Benefits of Targeted Delivery to the Colon
Dr. Luigi Moro, Chief Scientific Officer, Cosmo Pharmaceuticals
Inflammatory Bowel Disease - A New Horizon
Dr. Simon Travis, Consultant Gastroenterologist, John Radcliffe Hospital, Oxford, United Kingdom; Chairman of the Scientific Committee of the European Crohn's and Colitis Organization
Budesonide MMX(R) - Clinical Development Program in Ulcerative Colitis
Dr. E. David Ballard II, Senior Vice President, Clinical Research & Medical Affairs, Santarus, Inc.
Traveler's Diarrhea - #1 Health Risk for Travelers to Developing Countries
Dr. Robert Steffen, Professor Emeritus, University of Zurich Centre for Travel Medicine; Director, World Health Organization Collaborating Center for Travelers' Health
Rifamycin SV MMX(R) - Clinical Development Program in Traveler's Diarrhea
Dr. E. David Ballard II, Senior Vice President, Clinical Research & Medical Affairs, Santarus, Inc.
Summary/Question & Answer Session
Gerald Proehl, President, Chief Executive Officer & Director, Santarus, Inc.
About Santarus
Santarus, Inc. is a specialty biopharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by gastroenterologists and other targeted physicians. The company's current commercial efforts are focused on ZEGERID(R) (omeprazole/sodium bicarbonate) Capsules and Powder for Oral Suspension, which are indicated for the treatment of certain upper GI diseases and disorders, and on GLUMETZA(R) (metformin hydrochloride extended-release tablets), which are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. Santarus is also developing two late-stage lower GI product candidates, budesonide MMX(R) and rifamycin SV MMX(R) for the U.S. market. Budesonide MMX is being investigated in two multi-center Phase III clinical trials for the induction of remission of mild or moderate active ulcerative colitis. Rifamycin SV MMX has been investigated in a Phase II clinical program in traveler's diarrhea. More information about Santarus is available on the company's Web site at www.santarus.com.
Minimum Requirements to listen to broadcast:
The Windows Media Player software, downloadable free from http://www.microsoft.com/windows/windowsmedia/default.aspx and at least a 56Kbps connection to the Internet. If you experience problems listening to the webcast, send an e-mail to: webcast@multivu.com.
CONTACT: Amy Higgins, Lippert/Heilshorn & Associates, +1-310-691-7100,
ahiggins@lhai.com
